Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis

Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N467

Enrollment

Registered

2023-04-04

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Triflunomide tablet 14 mg daily plus silymarin tablet 140 mg twice daily for 2 months. Intervention 2: Control group: Triflunomide tablet 14 mg daily plus placebo t

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age 18 to 70 years Multiple sclerosis

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Alcohol consumption Active viral hepatitis or chronic liver disease

Design outcomes

Primary

Measure	Time frame
Liver and biliary function tests (including AST, ALT, ALP, bilirubin and GGT). Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: By laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRezvan Norouzi

Hamedan University of Medical Sciences

rezvannorouzi11@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026